Surge in Prostate Cancer Screening Following High-Profile Diagnosis Announcement

Hepatitis C is a liver infection caused by the hepatitis C virus. This virus spreads primarily through contact with infected blood. Many people with hepatitis C do not experience symptoms initially, which means the infection can go undetected for years while potentially causing liver damage. Testing for hepatitis C is essential for early detection and treatment, as chronic infection can lead to serious liver problems including cirrhosis and liver cancer.

Laboratory testing for hepatitis C typically involves a two-step process. The first test is an antibody test, which detects antibodies that your immune system produces in response to the hepatitis C virus. If this antibody test is positive, it indicates that you have been exposed to the virus at some point. However, a positive antibody test alone cannot determine whether you currently have an active infection or if your body has cleared the virus naturally or through treatment. This is why a second test is necessary.

The second test is called an HCV RNA test, which looks for the genetic material of the virus itself in your blood. This test confirms whether the virus is currently present and actively replicating in your body. If the HCV RNA test is positive, you have an active hepatitis C infection that requires medical attention. The RNA test can also measure the amount of virus in your blood, known as the viral load, which helps healthcare providers monitor the infection and evaluate treatment effectiveness.

Additional laboratory tests may be performed to assess liver function and determine the extent of liver damage. These include liver enzyme tests, which measure levels of proteins that leak into the bloodstream when liver cells are damaged. Your healthcare provider may also order tests to identify the specific genotype of the hepatitis C virus, as this information helps determine the most appropriate treatment approach. Regular monitoring through laboratory testing is important for people with hepatitis C to track disease progression and treatment response.